<DOC>
	<DOC>NCT01322438</DOC>
	<brief_summary>The purpose of this study is to see if giving rifampin, a marketed antibiotic, changes how your body absorbs and distributes BAY73-4506.</brief_summary>
	<brief_title>Effect of Rifampin on the Pharmacokinetics of BAY73-4506</brief_title>
	<detailed_description />
	<mesh_term>Rifampin</mesh_term>
	<criteria>Healthy male subject Age: 18 to 45 years (inclusive) at the first screening examination / visit Body mass index (BMI): 18 to 32 kg/mÂ² (inclusive) Ability to understand and follow studyrelated instructions Subjects enrolled in this study must use adequate barrier birth control measures prior to, during the course of the study, and 3 months after the last administration of regorafenib. An adequate contraception includes the use of condoms or a vasectomy. In addition, adequate birth control measures for the subject's partner is required, such as a hormonal contraception with implants or combined oral contraceptives, certain intrauterine devices, bilateral tubal ligation, or hysterectomy. Clinically significant disease or condition Recent serious infection</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>healthy volunteers</keyword>
	<keyword>rifampin</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>single dose</keyword>
</DOC>